<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01277575</url>
  </required_header>
  <id_info>
    <org_study_id>EBS-PP-2010-08-25-001</org_study_id>
    <nct_id>NCT01277575</nct_id>
  </id_info>
  <brief_title>Non-invasive Repetitive Paraorbital Alternating Current Stimulation Therapy for Aphasia</brief_title>
  <official_title>Multicenter Study of Non-invasive Repetitive Paraorbital Alternating Current Stimulation of the Brain: Therapy for Aphasy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Magdeburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EBS Technologies GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Magdeburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators assess if repetitive, transcranial alternating current stimulation (rtACS)&#xD;
      can improve the speaking quality of the aphasic patient as well as other communication skills&#xD;
      as naming, repeating and understanding spoken words, reading and writing. Further, it will be&#xD;
      assessed if memory and attentiveness deficiencies after 10 days of therapy with brain&#xD;
      stimulation are stabilized and remain stable after a training-free period of 60 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruitment efforts did not result in a sufficient number of patients&#xD;
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement of speaking</measure>
    <time_frame>between baseline and 60 days after stimulation</time_frame>
    <description>assessed by the following tests:&#xD;
Expressive speaking: ANELT (Amsterdam Nijmegen Everyday Language Test), Aachener Aphasie Test&#xD;
receptive speaking: ANELT (Amsterdam Nijmegen Everyday Language Test), Aachener Aphasie Test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>successful stabilization of language</measure>
    <time_frame>60 days after stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>speaking functions 1 - communicative skills</measure>
    <time_frame>baseline to 60 days after stimulation</time_frame>
    <description>reading and writing: Aachener Aphasy Test&#xD;
attentiveness: TAP test battery&#xD;
working Memory: Wechsler Memory scale-Revised (WMS-R)&#xD;
emitional state: Vision Analogous Mood Scale (VAMS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>speaking functions 2 - spontaneous speech faculty</measure>
    <time_frame>baseline to 60 days after stimulation</time_frame>
    <description>reading and writing: Aachener Aphasy Test&#xD;
attentiveness: TAP test battery&#xD;
working Memory: Wechsler Memory scale-Revised (WMS-R)&#xD;
emitional state: Vision Analogous Mood Scale (VAMS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>speaking functions 3 - naming</measure>
    <time_frame>baseline to 60 days after stimulation</time_frame>
    <description>reading and writing: Aachener Aphasy Test&#xD;
attentiveness: TAP test battery&#xD;
working Memory: Wechsler Memory scale-Revised (WMS-R)&#xD;
emitional state: Vision Analogous Mood Scale (VAMS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>speaking functions 4 - repeating</measure>
    <time_frame>baseline to 60 days after stimulation</time_frame>
    <description>reading and writing: Aachener Aphasy Test&#xD;
attentiveness: TAP test battery&#xD;
working Memory: Wechsler Memory scale-Revised (WMS-R)&#xD;
emitional state: Vision Analogous Mood Scale (VAMS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>speaking functions 5 - understanding</measure>
    <time_frame>baseline to 60 days after stimulation</time_frame>
    <description>reading and writing: Aachener Aphasy Test&#xD;
attentiveness: TAP test battery&#xD;
working Memory: Wechsler Memory scale-Revised (WMS-R)&#xD;
emitional state: Vision Analogous Mood Scale (VAMS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Aphasia</condition>
  <arm_group>
    <arm_group_label>Verum stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>repetitive transorbital alternating current stimulation (rtACS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham stimulation (placebo condition) no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>rtACS stimulation (Verum condition)</intervention_name>
    <description>Repetitive, transorbital alternating current stimulation (rtACS) is applied with multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 microA. Current intensity is individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation</description>
    <arm_group_label>Verum stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>placebo condition</intervention_name>
    <description>A clicking sound is presented and the same electrode montage set-up is used during rtASC- and Placebo-stimulation, except that placebo patients received no current (stimulator turned off).</description>
    <arm_group_label>Placebo stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  stroke&#xD;
&#xD;
          -  lesion age at least 6 months&#xD;
&#xD;
          -  aphasia with at least moderate severity according to Aachener Aphasia Test (AAT)&#xD;
&#xD;
          -  age between 40 and 75&#xD;
&#xD;
          -  German-speaking (at a native speaking level)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cognitive or speech-language therapy during the 2-weeks stimulation course&#xD;
&#xD;
          -  intensive language training when exceeding 1 hour, 2 times a week during the 2-weeks&#xD;
             stimulation course and the follow-up period (60 days after stimulation was completed)&#xD;
&#xD;
          -  additional neurological diseases, e.g. surgical brain tumor removal, untreated tumor&#xD;
             disease, acute traumatic brain injury, and/or craniotomy&#xD;
&#xD;
          -  (severe) dysarthria&#xD;
&#xD;
          -  untreated hypertension exceeding 160/100 mmHg (patients with treated hypertension and&#xD;
             blood pressure below 160/100 mmHg can be included)&#xD;
&#xD;
          -  increased risk of vascular thrombosis&#xD;
&#xD;
          -  epilepsy, photo sensitivity, acute focal findings (patients without focal findings or&#xD;
             epileptiform discharges can be included when they had only a single seizure more than&#xD;
             10 years ago)&#xD;
&#xD;
          -  dementias and neurodegenerative diseases&#xD;
&#xD;
          -  significant psychiatric disturbances, e.g. schizophrenia&#xD;
&#xD;
          -  major attention and/or memory deficits&#xD;
&#xD;
          -  major hearing loss&#xD;
&#xD;
          -  patients with uncorrected visual deficits&#xD;
&#xD;
          -  severe global aphasia&#xD;
&#xD;
          -  modality-specific disorders (pure speech apraxia, pure alexia, pure agraphia)&#xD;
&#xD;
          -  electric or electronic implants (e.g. heart pacemakers)&#xD;
&#xD;
          -  metal artefacts located at the head&#xD;
&#xD;
          -  medication with impact on the central nervous system (e.g. antidepressant or sedative&#xD;
             drugs)&#xD;
&#xD;
          -  participation in another trial&#xD;
&#xD;
          -  pregnant or breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernhard A Sabel, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Magdeburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurologische Klinik, Medizinische Fakult√§t der RWTH Aachen, Pauwelsstr. 30</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik, Brandenburg Klinik Bernau, Brandenburgallee 1</name>
      <address>
        <city>Bernau Waldsiedlung</city>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut f√ºr Medizinische Psychologie, Leipziger Str. 44</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>January 14, 2011</study_first_submitted>
  <study_first_submitted_qc>January 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2011</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <responsible_party>
    <name_title>Dr. Ephrat Lahmer-Naim, Clinical Trials Manager</name_title>
    <organization>EBS Technologies GmbH</organization>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>aphasia</keyword>
  <keyword>language</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aphasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

